# CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma

> **NCT05948033** · PHASE1,PHASE2 · RECRUITING · sponsor: **Chinese PLA General Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** CD70-targeting CAR-T cells

## Key facts

- **NCT ID:** NCT05948033
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-15
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-07-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05948033

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05948033, "CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05948033. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*